In general in medicine there is a move towards personalized treatment. This will be especially important for type 1 diabetes as this is a very heterogenous disease involving both genetic and environmental factors.
We reported earlier on the researchers’ first results with the diabetes vaccine Diamyd® (GAD65-alum). The researchers now report that the efficacy of Diamyd® is associated with the HLA-DR3-DQ2 and DR4-DQ8 haplotypes: people with type 1 diabetes with the DR3-DQ2 haplotype show a dose-dependent effect of the vaccine on residual C-peptide production (i.e. beta-cell function), especially when they are negative for genotypes that include the HLA-DR4-DQ8 haplotype. They explain their results in this Medical Expert Event.
These results contribute to stratifying people with type 1 diabetes based on on their genotype, facilitating and accelarating the development of immunomodulatory therapies for type 1 diabetes.